Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 311.50
Bid: 311.50
Ask: 316.00
Change: -7.00 (-2.20%)
Spread: 4.50 (1.445%)
Open: 325.00
High: 325.00
Low: 311.50
Prev. Close: 318.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: DFS Furniture gains share of weak market

Thu, 21st Sep 2023 09:40

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

----------

SMALL-CAP - WINNERS

----------

DFS Furniture PLC, up 4.9% 112.45p, 12-month range 101p-170p. The sofa retailer continues to win UK market share in a "very tough market" during its financial year, which ended on June 25, and outlines a path to improving margins. DFS says revenue from continuing operations fell 5.2% year-on-year to GBP1.09 billion from GBP1.15 billion, as pretax profit slumps 49% to GBP29.7 million from GBP58.5 million. Underlying profit before tax and brand amortisation is GBP30.6 million, which is in line with its interim guidance. DFS expects underlying profit before tax and brand amortisation to improve by a low single-digit percentage in financial 2024 to a GBP30 million to GBP35 million range. This assumes market volumes fall 5%, DFS notes. "We are confident the market will recover; however we can't predict how quickly that will happen. We have a clear route to a 5% [profit before tax] margin without market recovery, supported by further margin improvement, new cost efficiencies, and continued growth in Home," DFS says.

----------

Oxford BioMedica PLC, up 5.4% at 283.50 pence, 12-month range 236.50-575.00p. The cell and gene therapy company adds to Wednesday's gains after it announced exclusive talks with Institut Meriueux SA about buying ABL Europe, a pure-play European contract development and manufacturing organization. As part of the deal, Institut Merieux would become one of its major shareholders. The stock is down 16% over the past month however.

----------

SMALL-CAP - LOSERS

----------

James Fisher & Sons PLC, down 2.5% at 345.14p, 12-month range 241p-427.5p. The marine services swings to a pretax loss in the first half of 2023 of GBP4.4 million from a profit of GBP5.2 million a year before. This comes despite revenue rising 17% GBP252.0 million from GBP215.0 million. The loss is due to GBP9.3 million in refinancing legal and advisory costs, as well as higher interest rates, offsetting a positive operating performance, James Fisher explains. "All three divisions delivered revenue and profit growth against the first half of 2022, with a particularly strong increase seen in the Energy division," says CEO Jean Vernet. Trading in July and August is in line with its expectations, and James Fisher leaves its full-year expectations unchanged.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
12 Mar 2019 10:10

Oxford Biomedica enters research collaboration with Microsoft

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has entered into a research and development collaboration with Microsoft Research, it announced on Tuesday, to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning.

Read more
23 Nov 2018 10:59

Oxford BioMedica forms new digital framework initiative

(Sharecast News) - Gene and cell therapy group Oxford BioMedica announced the formation of a new digital framework initiative on Friday, which it said would streamline the production of next-generation medicines.

Read more
25 Oct 2018 10:14

First patient successfully dosed with Oxford BioMedica's OXB-102

(Sharecast News) - Gene and cell therapy group Oxford BioMedica noted on Thursday that its partner, Axovant Sciences - a company developing innovative gene therapies for neurologic and neuromuscular diseases - has announced the successful dosing of the first patient in a clinical study of AXO-Lenti-PD, also known as OXB-102.

Read more
13 Sep 2018 15:46

'Transformative year' sees Oxford Biomedica profit from two huge contracts

(Sharecast News) - Biopharmaceutical company Oxford Biomedica saw its shares rise on Thursday after its first half gross income more than doubled due to two huge contracts.

Read more
22 May 2018 16:13

UK Shareholder Meetings Calendar - Next 7 Days

Wednesday 23 MayBovis Homes GroupSt James's Place Keller GroupGamma Emerging

Read more
4 May 2018 11:57

Oxford BioMedica To Cut Share Capital Through Consolidation (ALLISS)

LONDON (Alliance News) - Oxford BioMedica PLC said Friday it is proposing reducing the issued share capital of the company by a factor of 50 through a share capital consolidation.On Oxford

Read more
15 Mar 2018 11:45

Oxford Biomedica Loss Narrows, Revenue Grows In Transformational 2017

LONDON (Alliance News) - Gene therapy firm Oxford Biomedica PLC said Thursday its 2017 loss narrowed after revenue grew significantly on product progress and finance costs in

Read more
9 Mar 2018 17:16

Oxford BioMedica To Raise GBP21 Million Via Discounted Share Issue (ALLISS)

LONDON (Alliance News) - Oxford BioMedica PLC said Friday it intends to raise GBP20.5 million via a accelerated share book build process to fund the expansion a

Read more
10 Oct 2016 14:19

Oxford BioMedica's RetinoStat achieves 'favourable safety profile' in tests

(ShareCast News) - AIM-listed pharmaceutical Oxford BioMedica's RetinoStat, the first ocular lentiviral gene therapy to be administered in humans, demonstrated a "favourable safety profile with no serious adverse events" in its phase one study. Results of the study, which were previously published i

Read more
28 Jul 2016 09:05

Oxford BioMedica Gets Approval To Manufacture Drugs At New Facilities

Read more
7 Jun 2016 06:48

Oxford BioMedica Signs New Non-Exclusive Licence Deal With MolMed

Read more
2 Jun 2016 11:03

LONDON MARKET MIDDAY: Platinum Firm Gleams Ahead Of ECB, OPEC Outcomes

Read more
2 Jun 2016 09:16

Oxford Biomedica Signs Collaboration Deal With Green Cross LabCell

Read more
31 May 2016 15:04

UK Shareholder Meetings Calendar - Next 7 Days

Read more
24 May 2016 10:42

DIRECTOR DEALINGS: Oxford BioMedica Chairman Ups Interest

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.